LBA2 Rates of pathologic complete response after VV1 and cemiplimab (alone and in treatment sequence-strategy) in the neoadjuvant setting: Results from the I-SPY 2.2 trial

Authors
Category Primary study
JournalESMO Open
Year 2025
This article has no abstract
Epistemonikos ID: ddb24b960102cc37b86076ac2f87822c6cd41c7e
First added on: May 17, 2025